CRISPR-edited allogeneic anti-CD19 CAR-T

· Caribou Biosciences, Inc.

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for CRISPR-edited allogeneic anti-CD19 CAR-T, covering 2025-03-24 to 2025-03-24. Get the full timeline:

Most recent: Clinical Trial Update: CRISPR-Edited Allogeneic Anti-CD19 CAR-T Cell Therapy for Relapsed/Refractory B Cell Non-Hodgkin Lymphoma (ANTLER) [Phase 1]

See pricing